Medicine & Pharmaceuticals News
One Metro, Two States: What Kansas City Families Should Know When a Death Crosses the State Line
Kansas City is one community in most ways that matter. People live in Overland Park and work downtown, shop in Olathe and see doctors in Missouri, and cross State Line Road without a second thought. But when a loved one dies unexpectedly, that invisible line can suddenly matter a great deal, and many families are left unsure which system is handling what. Postmortem Pathology, a forensic pathology practice serving the Kansas City metro, is working to help families understand that their options for a private autopsy in Kansas City don't depend on which side of the line a death occurred. The practice provides independent autopsy services to families throughout the region, including Kansas City, Kansas, Johnson County and the Missouri side of the metro. "We hear the same thing from families all the time: he lived in Kansas, he passed away at a hospital in Missouri, and nobody could tell us who to call," said Dan Lingamfelter, D.O., Lead Pathologist at Postmortem Pathology. "That confusion comes at the worst possible moment. Our job is to take that uncertainty off the family's plate." Two States, Two Systems When someone dies, the investigation falls under the rules of the place where it happened, not the place they called home. That distinction matters in the Kansas City region, where Missouri and Kansas each run the process their own way. That means a family in Kansas may find themselves dealing with offices, paperwork and timelines in Missouri, or the other way around, often with little explanation. An independent autopsy in Kansas City gives families a separate path forward, whether or not an official examination has already taken place. The goal is a clear, thorough answer about cause of death from someone working on the family's behalf. Who Performs an Autopsy? Many families are surprised to learn who performs an autopsy in Kansas City . A private examination is conducted by a forensic pathologist in Kansas City , a physician trained specifically to determine how and why a person died. Dr. Lingamfelter is board-certified in anatomic, clinical and forensic pathology.
Before Cremation: The Decision Window Colorado Families Don't Know They Have
TrustCare Med Launches September 30 With Simultaneous Entry Into Colombia And Mexico
Temecula Contractor Urges Homeowners to Plan Patio Covers Now, Ahead of the Rainy Season and the Spring Building Rush
- September 23, 2026Medicine & Pharmaceuticals
PrymaLab Publishes Lot Testing Documentation Standards And Free Peptide Concentration Calculator
PrymaLab has published the analytical documentation standards it applies to each production lot, and has released a free calculator that performs concentration arithmetic. Both are reference materials rather than product offerings, and both are available without charge or registration. According to documentation published by the company, each lot is analysed by high performance liquid chromatography and by mass spectrometry, samples are submitted to an independent third-party laboratory for confirmation of identity and purity, and a lot-specific certificate of analysis is issued with the lot. Certificates correspond to the lot they describe and are available on request. Synthesis, lyophilization and filling are carried out at the company facility in Ashland, Kentucky. These statements describe the company's own documented procedures and have not been independently audited or certified by any external body. The free peptide calculator converts a stated quantity of material and a stated volume of diluent into a concentration. It performs unit arithmetic only. It does not generate protocols, recommend quantities, propose schedules or interpret results, and it carries the same laboratory research use only notice as the rest of the company's published material. The published standards address a recurring ambiguity in how analytical certificates are read. Two figures commonly appear on peptide documentation and are frequently treated as interchangeable. Chromatographic purity describes the proportion of peptide-related material in a sample that is the target compound. Net peptide content describes the proportion of the total lyophilised mass that is peptide, with the remainder consisting of counterions, bound water and residual salts. Sigma-Aldrich sets out the relationship between the two figures in its technical documentation on peptide sample amount determination, and Bachem defines both terms in its quality control guide for amino acids and peptides. The two figures are independent, so a purity result on its own does not establish how much peptide a container holds. By way of arithmetic illustration only, a container labelled at 10 mg and reported at 99% chromatographic purity would hold approximately 7.9 mg of peptide if its net peptide content were 80%. The 80% figure is an assumption used to demonstrate the calculation. It is not a specification, not a measured value, not a typical value for any particular compound, and not a figure applicable to any PrymaLab material. AmbioPharm describes typical net peptide content as falling between 70 and 90%, while AAPPTEC gives a wider range of 50 to 90% depending on sequence, synthesis route and purification method. Net peptide content is sequence-dependent and has to be measured for each material rather than inferred from a purity figure. Counterion content is a further variable that a purity figure does not describe. Trifluoroacetate is a common residue of reversed-phase purification. Cornish and colleagues reported in the American Journal of Physiology in 1999 (PMID 10567002) that trifluoroacetate inhibited proliferation of osteoblasts and chondrocytes in culture. That result is specific to the cell types, concentrations and conditions examined in that study and should not be generalised to other systems or read as a statement about any product. Analytical certificates describe material as it was on the date of analysis. Oxidation, hydrolysis and deamidation proceed during storage, which makes the date of analysis a parameter needed to interpret a purity figure rather than administrative metadata. The company has published a set of reference articles covering analytical methods and individual compounds, each citing primary literature and stating where published evidence is limited, contested or absent. The reference on peptide purity testing sets out the material summarised above in full, with sources. All materials supplied by PrymaLab are sold for laboratory research use only. They are not drugs, are not dietary supplements, and are not approved by any regulatory authority for human or veterinary use. Nothing in this release describes safety, efficacy, therapeutic benefit, or any intended use in humans or animals. Introduction into humans or animals is prohibited. The calculator and the published documentation standards are available now. ABOUT PRYMALAB PrymaLab is a veteran-owned research chemical laboratory in Ashland, Kentucky, supplying materials to laboratories and qualified researchers for laboratory research use only. Synthesis, lyophilization and filling are performed in Ashland, and each lot is released with a lot-specific certificate of analysis.
- September 22, 2026Medicine & Pharmaceuticals
Delta Clinics Strengthens Patient Safety with a New Clinical Governance Framework
Delta Clinics has announced it has reached another milestone in patient safety, introducing enhanced standards designed to address growing public concern around patient wellbeing. The initiative brings together a structured framework that highlights verified clinical practices, surgeon credentials, and facility standards. Photo Courtesy of Delta Clinics "People travel by car daily and fly regularly without significant concern, yet these activities carry measurable risk," said Mr Hazem Alfie, lead consultant plastic surgeon at Delta Clinics. "When surgical procedures are performed by qualified specialists in proper clinical settings with appropriate patient selection, the risks are well understood and managed." This latest milestone directly addresses that issue by formalising a set of standards grounded in established medical guidelines. The framework places strong emphasis on comprehensive patient assessment, including detailed medical history reviews and evaluation of individual risk factors prior to any procedure. Candidates are assessed not only for physical suitability but also for realistic expectations, reducing the likelihood of complications and dissatisfaction. Surgical protocols at Delta Clinics incorporate evidence-based techniques and advanced anaesthetic methods, including Total Intravenous Anaesthesia (TIVA), administered by experienced anaesthetic consultants. These methods are supported by recovery protocols designed to minimise complications and promote consistent post-operative outcomes. Patients are monitored throughout their recovery with structured follow-up care, including guidance on mobility, pain management, and healing progression. This step forward also reflects broader industry standards that define safe surgical practice. Surgeons are expected to hold General Medical Council specialist registration and maintain affiliations with recognised professional organisations such as the British Association of Aesthetic Plastic Surgeons and the British Association of Plastic, Reconstructive and Aesthetic Surgeons. Facilities must meet strict accreditation requirements, with access to emergency equipment and established clinical protocols. Patient selection remains a defining factor in surgical safety. Not all individuals are suitable candidates for every procedure, and responsible practitioners decline cases where risk factors outweigh potential benefits. This principle is embedded within Delta Clinics' operational standards. "Safety in surgery depends on multiple factors working together," Mr Alfie added. "Qualified surgeons, accredited facilities, careful patient selection, and consistent aftercare all contribute to strong outcomes." Delta Clinics operates from locations in Harley Street and Finchley. This latest milestone marks a formal step toward increasing transparency and reinforcing clinical accountability within the sector. The clinic stated that the program is intended to provide patients with clearer benchmarks when evaluating providers. Initiatives that emphasise measurable safety standards are expected to play a central role in shaping public confidence. For more information, visit https://deltaclinics.co.uk/ About Delta Clinics UK Delta Clinics UK is a UK-based provider of regulated surgical care with clinics in Harley Street and Finchley. Consultation, surgery, and recovery care are delivered within facilities the company owns and operates. Delta Clinics UK works to documented standards for patient assessment, surgeon credentials, and post-operative care.
- September 18, 2026Medicine & Pharmaceuticals
Altapeptides Launches Online Catalogue for Laboratory Research Peptides
Altapeptides launched its online catalogue of laboratory research peptides on 15 September 2026, giving UK researchers access to a range of lyophilised compounds. The catalogue is designed for laboratories sourcing compounds for in-vitro and analytical work. Retatrutide is listed as a 40 mg lyophilised powder in a sealed 3 mL glass vial, and GHK-Cu is the copper(II) complex of glycyl-L-histidyl-L-lysine, listed as a 50 mg blue lyophilised powder in a sealed 3 mL glass vial. Product pages on the Altapeptides site set out each compound's composition, molecular weight, vial specification and storage conditions; both sealed vials require storage at 2–8 degrees Celsius, protected from light. Altapeptides operates a policy of publishing a certificate of analysis matched to each lot before that lot is dispatched, tying every vial to its printed lot number. First lots are pending, and their certificates have not yet been published. The certificates register currently displays compound names, vial sizes and specifications, with the lot entries marked as pending. Once published, certificates set out mass spectrometry identity, HPLC purity, residual-solvent and bacterial-endotoxin testing alongside the matching vial lot number, laboratory name and report number. "Researchers need clear specifications and a way to match a vial to its documentation," said Julian Vance, Director of Altapeptides. "Our policy is that no vial is dispatched without its certificate." All products in the catalogue are restricted to laboratory, analytical and in-vitro research use and are not intended for human or veterinary, diagnostic or therapeutic use. Orders are restricted to researchers aged 18 and over. Correspondence indicating an intended human use results in the order being refused. About Altapeptides Altapeptides is a UK-based supplier of lyophilised research peptides and analytical laboratory reagents headquartered in Shrewsbury. Its website brings together product specifications, a certificates register and research-use policies. The site also provides a journal and information on laboratory storage and handling of peptide reagents.
- September 17, 2026Medicine & Pharmaceuticals
Protheragen Launches Artificial Intelligence Services for Rare Disease Drug Discovery
As the application of artificial intelligence technology in life science research continues to develop, Protheragen has launched artificial intelligence services for rare disease research to provide AI-driven research support for scientific research institutions, biotechnology companies, and pharmaceutical companies. The service uses artificial intelligence technology to support data analysis, target identification, and biomarker discovery in rare disease research, helping researchers explore new research directions. Rare disease research often faces challenges such as complex disease mechanisms, limited research data, and difficulties in the discovery of potential therapeutic targets. With the continuous accumulation of genomics, multi-omics, and other biomedical data, how to discover valuable information from complex data has become an important topic to promote the research of rare disease drugs. The development of artificial intelligence technology provides researchers with new data analysis methods, which helps to support the research of disease mechanisms and the exploration of candidate therapeutic directions. For the data analysis and research needs in rare disease research, Protheragen provides artificial intelligence services for rare disease research and applies artificial intelligence technology to the process of rare disease-related research. The service provides technical support for scientific research teams, including biomedical data analysis, target identification, and biomarker research, and helps researchers better use complex research data to carry out follow-up research. In AI-driven rare disease drug discovery, Protheragen uses artificial intelligence methods to support the identification of potential therapeutic targets and related predictive analysis. Through the analysis of biomedical data, researchers can further explore disease-related mechanisms and candidate research directions, and provide data support for rare disease drug discovery-related research . In addition, Protheragen also provides artificial intelligence for biomarker discovery services, combining artificial intelligence methods with multi-omics data analysis to support potential biomarker discovery and disease-related research. By analyzing different types of biological data, the service helps researchers explore disease characteristics and provides data references for subsequent research. As a research service provider focused on life science research support, Protheragen continues to improve its service system related to rare disease research, combining artificial intelligence, bioinformatics analysis, and drug development-related research, providing professional research support for scientific research institutions, biotechnology enterprises, and pharmaceutical enterprises to promote the application of artificial intelligence technology in the field of rare disease research. About Protheragen Protheragen is a research service provider focused on life science research support. It provides rare disease research, drug development, bioinformatics analysis, and related scientific research and technology services for global scientific research institutions, biotechnology companies, and pharmaceutical companies. The company is committed to helping customers advance life science-related research through specialized research support.
- September 17, 2026Medicine & Pharmaceuticals
DailyColours Launches Mediterranean Plant Supplement Backed by University Clinical Trials
DailyColours, a British supplement brand, has launched a product that combines extracts of 16 Mediterranean fruits, vegetables, and herbs in a single daily supplement. The company states the formula delivers more than 160 colour phytonutrients across red, blue-purple, green and orange-yellow plant groups, and places it within a category it calls colour nutrition. Photo courtesy of Sara Dubler The idea rests on a straightforward premise: the pigments in plants are themselves nutrients. Carrots carry the orange pigment beta carotene, tomatoes carry red lycopene, and berries carry nutrients like resveratrol in their deep blue-purple tones. DailyColours’ research links these pigments to many of the health benefits of the Mediterranean diet, one of the most studied patterns of eating associated with long-term health. The company says few people eat a wide range of colourful plant foods each day. It presents the supplement as a way to narrow the distance between what the Mediterranean diet offers and what modern routines often allow. DailyColours says its launch follows four years of research, including a pilot study at King's College London and a randomised, placebo-controlled trial at the University of Exeter involving 150 adults aged 50 and over. According to research reports, participants recorded significant gains in cognitive performance and physical fitness, alongside changes in immune and inflammation markers. The trial summary states that "DailyColours supplementation mimics many of the Mediterranean Diet effects." Findings linked to the product were presented during 2025 at the Alzheimer's Association International Conference in Toronto, the International Congress of Nutrition in Paris, and the Phytochemicals and Health Symposium in Exeter. The company says it has secured multiple international patents tied to its finding that the four plant colour groups produce a stronger age-related health effect together than any single group alone. The patent record describes the discovery as "the biochemical basis for the health benefits of the Mediterranean Diet." The brand frames its work around health span rather than lifespan alone. DailyColours is sold online only . DailyColours also works with the National Centre for Integrative Medicine. About DailyColours DailyColours is a British supplement brand focused on healthy ageing through colour nutrition derived from the Mediterranean diet. Its product blends extracts from 16 Mediterranean fruits, vegetables, and herbs to deliver more than 160 plant phytonutrients, supported by clinical research conducted at King's College London and the University of Exeter.
- September 16, 2026Medicine & Pharmaceuticals
Eye Drops and Lubricants Market Expected to Reach USD 12028 Million by 2035
360 Research Reports projects that the Eye Drops and Lubricants market is estimated at USD 10629.15 million in 2026, increasing to USD 10775.83 million in 2027 and forecasted to hit USD 12028 million by 2035, exhibiting a CAGR of 1.38%. Market growth is supported by the expanding burden of dry eye disease, prolonged digital-device exposure, aging populations, contact-lens use, ocular irritation, and increasing demand for preservative-free and condition-specific eye-care products. For detailed segmentation, regional breakdowns, and competitive analysis, visit: https://www.360researchreports.com/market-reports/eye-drops-and-lubricants-market-206005 Why Eye Drops and Lubricants Are Becoming Essential for Modern Eye Care Digital-device usage, aging populations, contact-lens adoption, and increasing awareness of ocular health are changing how consumers manage eye discomfort. Eye drops and lubricants provide convenient support for dryness, irritation, tear-film instability, contact-lens discomfort, and other ocular-surface symptoms. Artificial tears remain the largest product category, while preservative-free formulations are gaining attention among consumers requiring frequent application. Approximately 20% of adults globally experience dry eye symptoms, while adults aged 50 years and older account for approximately 38% of regular lubricant use. Preservative-free formats represent nearly 44% of newly introduced lubricant products, highlighting the industry's shift toward improved tolerability and long-term use. Digital Eye Strain Is Creating a Recurring Demand Base Longer exposure to smartphones, computers, tablets, and other digital displays is increasing demand for everyday lubrication products. Approximately 62% of office-based adults report symptoms associated with prolonged digital viewing, while around 29% of contact-lens users regularly apply lubricating drops. Extended screen exposure can reduce blinking frequency and contribute to tear-film instability, dryness, irritation, and blurred vision. Around 64% of working-age adults use digital devices for more than six hours daily, while approximately 43% of consumers experiencing screen-related symptoms use eye drops several times per week. This is supporting a transition from occasional use toward recurring eye-care routines. Preservative-Free Formulations Are Reshaping Product Development Preservative-free eye drops are moving from specialist products toward mainstream eye-care solutions. Approximately 67% of ophthalmic professionals favor preservative-free lubricants for patients requiring frequent daily application. Manufacturers are responding with filtered multidose bottles, single-dose vials, unidirectional valves, and sterile dispensing systems designed to reduce contamination risks. Lipid-enhanced artificial tears are also gaining attention because evaporative dry eye represents nearly 80% of diagnosed dry eye cases. Gel drops and higher-viscosity lubricants are expanding within nighttime and severe-symptom routines, while lighter formulations continue to support daytime use. Artificial Tears Lead the Product Landscape Artificial tears account for the largest product share at 58%, supported by broad usage across diagnosed dry eye, digital eye strain, aging-related tear deficiency, environmental exposure, and contact-lens discomfort. Antibiotics represent 19%, Hormone products account for 8%, and Others contribute 15%. Artificial tears also benefit from high levels of non-prescription purchasing, with approximately 61% of users purchasing these products without a new prescription. North America Leads the Global Market North America holds a 36% market share, supported by established ophthalmology services, extensive retail distribution, high digital-device exposure, and strong awareness of dry eye management. Europe accounts for 27%, while Asia-Pacific represents 28%. Middle East and Africa contribute 6%, and REST OF WORLD accounts for 3%. The United States represents nearly 86% of North American demand, while China, Japan, India, South Korea, and Australia collectively represent nearly 78% of Asia-Pacific demand. Leading Eye Drops and Lubricants Companies The competitive landscape includes Abbott, Clear Eyes, ALCON, Allergan, SIMILASAN, Rohto, TheraTears, Sager Pharma, Bausch + Lomb, and Johnson & Johnson Services, Inc. ALCON and Bausch + Lomb Maintain Strong Market Positions ALCON holds an estimated 17% market share, supported by its artificial-tear portfolio, clinical relationships, preservative-free multidose technologies, lipid-supporting formulations, and global distribution. Bausch + Lomb accounts for approximately 15% market share, supported by its broad portfolio of lubricating drops, contact-lens rewetting products, prescription ophthalmic treatments, and other eye-health products. Investment and Product Development Opportunities Investment is increasingly focused on preservative-free formulations, sterile dispensing technologies, longer-lasting hydration, and tear-film stabilization. Approximately 43% of product-development programs prioritize multidose preservative-free packaging, while 32% focus on tear-film stabilization through hyaluronic acid, lipids, electrolytes, and moisture-retaining polymers. Asia-Pacific also provides significant expansion potential, accounting for 28% of current demand while representing more than 55% of the global population. Recent Market Developments Key developments during 2025–2026 include Clear Eyes and Rohto recalls related to sterility assurance, Bausch + Lomb's introduction of two preservative-free Blink products, ALCON's approval of TRYPTYR 0.003%, and the launch of SYSTANE PRO Preservative-Free. Download Free Sample Report https://www.360researchreports.com/enquiry/request-sample-pdf/eye-drops-and-lubricants-market-206005
- September 14, 2026Medicine & Pharmaceuticals
Alfa Cytology Provides Customized In Vivo Tumor Model Services to Support Preclinical Oncology Drug Efficacy Evaluation
As the development of oncology drugs continues to advance, researchers have an increasing demand for reliable research models that can support the preclinical evaluation of candidate drugs. Alfa Cytology provides customized in vivo tumor models , including xenograft models and patient-derived tumor models, to support biotechnology companies, pharmaceutical companies, and scientific research institutions in oncology drug research and efficacy evaluation. In recent years, the complexity of tumor biology has driven the development of more diverse preclinical research models. In the drug development process, in vitro experiments can help researchers initially evaluate the effects of candidate compounds, but in vivo tumor models can further support the comprehensive evaluation of tumor growth, treatment response, and drug efficacy. Therefore, how to select the appropriate research model and obtain reliable experimental data has become an important consideration in the process of oncology drug development. However, different types of candidate drugs and cancer research projects usually have different experimental requirements, and a single model system may not meet all research objectives. Researchers need to choose the appropriate model platform according to the tumor type, research purpose, and experimental design requirements. Establishing animal tumor models that meet the research needs and obtain reference values for drug efficacy evaluation data in the preclinical stage has become one of the important challenges to promote the development of cancer drugs. To meet the growing demand for preclinical studies, Alfa Cytology provides customized in vivo tumor model services to support researchers in conducting different types of in vivo tumor studies. The company's service system covers Cell Line-derived Xenograft (CDX) mouse models, Patient-derived Xenograft (PDX) models, and other tumor model platforms, which can be used for tumor growth analysis, treatment response evaluation, and preclinical study of candidate drugs. In the field of cancer research, Alfa Cytology provides cancer animal model services that can be customized according to different research project requirements, helping researchers to carry out in vivo experimental evaluation for different tumor types. By using the established tumor model platform, the research team can further analyze the effect of candidate drugs in the in vivo environment and provide experimental data support for subsequent drug development research. In addition, Alfa Cytology can provide corresponding tumor model research protocols according to the needs of customer projects to assist researchers in selecting experimental strategies that are suitable for their research objectives. Through its tumor model research services, Alfa Cytology is committed to providing technical support for cancer research and drug discovery programs. About Alfa Cytology Alfa Cytology is a professional service provider focused on life science research and drug development support, providing related research services to scientific research institutions, biotechnology companies, and pharmaceutical companies. The company's services include oncology research, drug discovery, preclinical research, and related biotechnology services to support the development and evaluation of innovative therapeutic approaches.
- September 10, 2026Medicine & Pharmaceuticals
Hudson Hedge Capital Provides Strategic Development Update on CINV
Hudson Hedge Capital has provided a strategic update concerning Crucial Innovation Inc. ("CINV"), a private company developing an integrated pharmaceutical botanical therapeutics platform. CINV is working to transform regulated plant-derived compounds into standardised active pharmaceutical ingredients, clinically governed formulations and scalable finished-dose medicines. Its developing platform is intended to span cultivation, pharmaceutical-grade processing, formulation, clinical research and regulated patient access. Medical cannabis provides the current commercial foundation, while additional botanical compounds may present longer-term development opportunities. Any product development, therapeutic application or research programme remains subject to scientific validation, successful clinical development and applicable regulatory approvals. Proposed Transaction with Nasdaq-Listed 707 Cayman Holdings On 25 August 2026, Nasdaq-listed 707 Cayman Holdings Limited announced that it had entered into a non-binding term sheet to acquire CINV. According to that announcement, the proposed combination is intended to bring together CINV's botanical therapeutics platform and 707 Cayman Holdings' existing public-market infrastructure. The proposed transaction is not a completed acquisition or confirmed public listing for CINV. It remains subject to satisfactory due diligence, delivery of PCAOB-audited financial statements, execution of definitive agreements and applicable corporate, shareholder, regulatory and Nasdaq approvals. The final transaction structure, valuation, consideration, capital arrangements and allocation of proceeds have not been confirmed. There is no assurance that the transaction will be completed on the terms presently contemplated, within a particular timeframe or at all. Private-Market Reference Information As part of CINV's private capital planning, indicative reference information has included a private share reference price of US$1.09 per share, an indicative company valuation of approximately US$128 million, potential private transaction sizes beginning from approximately US$100,000, and an illustrative future valuation scenario equivalent to US$2.52 per share. These figures are included solely to explain elements of the company's current private-market planning. They have not been independently verified and must not be interpreted as an offer price, public subscription invitation, expected trading price, investment recommendation or guarantee of future value. In particular, the US$2.52 figure represents an illustrative management scenario, not a formal price target, independent valuation opinion or prediction. It depends on numerous assumptions, including operational execution, financing, dilution, regulatory progress, scientific development, market conditions and the structure and completion of future corporate transactions. No assurance can be given that this scenario will be achieved. Private Capital Activity Hudson Hedge Capital has supported CINV's private capital planning and related strategic discussions. Any potential securities transaction will be considered separately from this public announcement and may be made available only through confidential documentation to persons who have first been assessed as eligible under the laws and regulations applicable to them. No person may subscribe for or acquire securities on the basis of this announcement. Any potential transaction will be subject to availability, investor eligibility, appropriate know-your-client and anti-money-laundering checks, satisfactory due diligence and executed definitive documentation. The reference to potential transaction sizes beginning from US$100,000 does not constitute an invitation to invest and does not mean that an investment is available to any particular person or in any particular jurisdiction. Strategic Roadmap CINV's current roadmap includes the continued development of its pharmaceutical botanical platform, expansion of regulated routes to market, advancement of its research infrastructure and completion of the work required in connection with the proposed transaction. These are objectives rather than confirmed outcomes. Their timing and completion will depend on financing, regulatory requirements, scientific and commercial progress, market conditions and other factors outside the control of CINV or Hudson Hedge Capital. Hudson Hedge Capital will continue to monitor the company's progress and expects further factual updates to be issued when material developments have been completed or formally confirmed. About CINV Crucial Innovation Inc. is developing an integrated pharmaceutical botanical therapeutics platform spanning cultivation, GMP processing, formulation, clinical research and regulated patient access. The company's stated mission is to transform regulated plant-derived compounds into standardised APIs, clinically governed formulations and scalable finished-dose medicines. About Hudson Hedge Capital Hudson Hedge Capital is an independent investment and advisory firm headquartered in Dubai. The firm works with private clients, family offices and corporate entities across strategic investment planning, private markets and multi-asset investment strategies. Email directly to [email protected] .
- September 4, 2026Medicine & Pharmaceuticals
Veneers Dominican Republic Expands Focus on International Patient Services
Veneers Dominican Republic, a cosmetic and restorative dental practice led by Dr. Jonathan Collado, is expanding its focus on serving international patients seeking cosmetic dental treatment in Santo Domingo. The practice's international patient activity reflects growing interest in accessing cosmetic dentistry outside patients' home countries while maintaining specific expectations regarding clinical experience, treatment planning, materials and laboratory work. Miami-based fashion and media professional Anna Estrin is among the international patients who researched cosmetic dentistry options in the Dominican Republic. Estrin began considering treatment abroad after comparing the cost of a complete smile transformation in the United States with international alternatives. During her research, Anna Estrin reviewed cosmetic cases by Dr. Jonathan Collado and focused on factors including tooth shape, proportions, translucency and surface texture. Her evaluation illustrates the range of considerations international patients may use when selecting a cosmetic dentistry provider. “I wanted an experienced doctor, advanced technology, excellent laboratory work and the newest generation of veneers, but most importantly, I wanted a beautiful, natural result,” said Anna Estrin. As part of its work with international patients, Veneers Dominican Republic provides consultations and treatment planning for cosmetic procedures including E-max and porcelain veneers, Lumineers and composite veneers. Treatment plans are determined according to each patient's individual dental condition and goals. For patients traveling internationally, treatment duration can also be an important logistical consideration. According to the practice, some cosmetic smile transformations may potentially be completed during a stay of approximately five days, depending on the patient's condition and treatment plan. This timeframe was particularly relevant to Anna Estrin because of her professional schedule. The practice emphasizes that patients considering treatment abroad should independently evaluate the dentist's experience, proposed materials, laboratory standards, treatment plan and aftercare. Cost, the clinic notes, should be considered alongside these factors rather than used as the sole basis for a medical decision. Veneers Dominican Republic's continued focus on international patients represents an expansion of its existing cosmetic and restorative dental services in Santo Domingo. About Veneers Dominican Republic Veneers Dominican Republic is a cosmetic and restorative dental practice in Santo Domingo led by Dr. Jonathan Collado, serving domestic and international patients.
- September 2, 2026Medicine & Pharmaceuticals
Global Nest Family Receives 2026 Global Recognition Award for International Family-Building Support
Global Nest Family has received a 2026 Global Recognition Award for Customer Experience, in recognition of its support for families navigating international surrogacy and IVF arrangements. The award reflects the organization’s work providing practical information, administrative assistance, and communication for intended parents managing medical, legal, travel, and financial matters. Photo Courtesy of Global Nest Family Founded in 2019, Global Nest Family works with families pursuing parenthood across borders, where procedures may involve several jurisdictions, clinics, service providers, and local requirements. The organization supports clients through consultations, treatment planning, documentation, travel preparation, legal procedures, and birth registration requirements. Support Through Complex Journeys Global Nest Family was created after its founders experienced the practical difficulties of seeking surrogacy abroad as intended parents. The organization coordinates communication between families, clinics, and local teams while helping clients prepare documents and manage logistical requirements associated with cross-border arrangements. Its services include surrogacy matching, self-cycle IVF, donor cycles, and frozen embryo transfers, with coordination adapted to each destination and case. “International family-building arrangements can change quickly, particularly when medical schedules, documentation requirements, or travel plans need revision,” Global Nest Family stated. “The priority is to give families clear information, maintain continuity, and help them understand the available options at each stage.” The organization’s customer experience model emphasizes continuity. Its multilingual team is available around the clock, enabling clients to communicate with staff members familiar with their circumstances rather than repeatedly explaining sensitive information to new contacts. This arrangement supports families when treatment is delayed, a transfer does not proceed as expected, or clinical information requires a revised plan. Global Nest Family reports that more than 150 babies have been born through journeys it has supported and that families from more than 40 countries have used its services since operations began. The organization’s work requires coordination across languages, legal frameworks, administrative systems, and travel conditions. International Service And Inclusion Global Nest Family operates programs in Georgia, Mexico, Ukraine, Albania, and Thailand. Each location has separate requirements relating to medical coordination, legal documentation, travel planning, and local administration. The organization assists intended parents in reviewing program structures and communicating with the teams involved in their arrangements. “Families do not begin these processes from the same legal position, family structure, or cultural context,” Global Nest Family stated. “Support must account for those differences without reducing a complex personal decision to a standard process.” The organization works with intended parents from varied backgrounds, including LGBTQ+ people and unmarried clients, who may face additional barriers while pursuing parenthood. Its stated approach includes selecting IVF clinics, embryologists, and program structures independently, allowing recommendations to be considered according to quality, suitability, and operational requirements rather than commercial affiliation. Its inclusion work includes community support in countries where it operates. Since 2022, Global Nest Family has helped Saakroaa school in Thailand provide two meals per day for an average of 50 to 75 children from low-income families. The contribution has supported an estimated 12,000 to 16,000 meals annually. Since 2020, the organization has also supported Wave in Georgia and provided clothing, equipment, and toys for women and children. Final Words “The assessment identified a service model based on continuity, practical coordination, and respectful communication during a period of uncertainty for many families,” Alex Sterling, spokesperson of Global Recognition Awards, said. “Global Nest Family’s work demonstrates that customer experience includes routine assistance as well as ongoing support when circumstances become more difficult.” Global Recognition Awards assessed Global Nest Family through an initial screening by industry experts. The evaluation considered eligibility, industry recognition, innovation, leadership, service, sustainability, and social responsibility. Shortlisted applicants were rated on a scale of 1 to 5 and evaluated using the Rasch model, a measurement method intended to support consistent comparisons across categories and organizational performance. The recognition follows an evaluation of Global Nest Family’s support for families managing cross-border coordination and its community involvement in Thailand and Georgia. Its assistance has focused on food provision, material support, safety, and stability for children and women. About Global Recognition Awards Global Recognition Awards is an international organization that recognizes exceptional companies and individuals who have made significant contributions to their industries.
- August 27, 2026Medicine & Pharmaceuticals
Pure Derma Clinic Highlights Doctor-Led Aesthetic Treatments
Pure Derma Clinic highlights its doctor-led aesthetic treatments in Greenford for clients seeking natural-looking facial enhancement through personalised, clinically informed care. The clinic’s approach centres on individual consultations, treatment planning, and medically guided aesthetic care designed to support subtle and balanced outcomes. Pure Derma’s treatment in Greenford reflects this focus on personalised care and natural-looking results. “Patients often want to look refreshed and balanced without appearing overtreated, so each consultation is approached with careful assessment, medical guidance, and respect for the individual’s natural features,” said a representative of Pure Derma Clinic. The announcement reflects the clinic’s continued focus on non-surgical facial aesthetics delivered through a safety-conscious and patient-centred process, where treatment plans are shaped around facial harmony, skin quality, age-related concerns, comfort, and realistic outcomes rather than standardised procedures. Pure Derma’s treatment in Greenford includes options such as lip enhancement, tear trough treatment, cheek fillers, chin and jawline contouring, nose reshaping, nose-to-mouth fold treatment, wrinkle reduction, and non-surgical facelift planning, with each service assessed according to the client’s facial structure, treatment history, and personal expectations. Led by Dr Ali, the clinic places emphasis on consultation, hygiene, aftercare, and measured treatment planning, which are particularly important for first-time clients and individuals who may feel cautious about aesthetic procedures. The approach is designed to support subtle definition, restored volume, smoother facial lines, improved skin appearance, and a more refreshed look while maintaining natural expression and proportion. Pure Derma Clinic also recognises that modern aesthetic clients increasingly seek clinical reassurance as well as refined results, especially when considering injectable or skin-focused treatments for the first time. By combining medical oversight with advanced techniques and a calm treatment environment, the clinic aims to help local Greenford residents and West London professionals make informed choices about facial enhancement without unnecessary pressure, excessive claims, or a one-size-fits-all treatment model. Appointments are available during weekday and Saturday opening hours, allowing local clients to access consultation-led care around professional and personal schedules while receiving clear guidance before, during, and after treatment.
ALL NEWS
- Openness Navigates Change, Cooperation Creates Tomorrow—Closing of the 26th China International Fair for Investment & Trade
- CIFIT: From Promoting Cross-Strait Economic and Trade Exchanges to Deepening Cooperation and Delivering Tangible Results
- Scalimed Connects Patient Inquiries to Scheduled Consultations
- THE COOP launches an AI-native challenger to iGaming media
- DS18 Brings Three Custom Audio Builds and PROJECT360 to SEMA 2026, Featuring JUCA's Hot Wheels Kool Kombi
- Broward County Criminal Defense Attorney Matthew Glassman Warns Residents About Price Gouging, Looting, and Curfew Charges as Hurricane Season Peaks
- DigitalSign.co Launches AI-Powered Digital Signage Platform for Businesses Managing Screens at Scale
- New UK Parcel Site Parcel Match Takes On Courier Giants Over Hidden Fees
- October 2026 Industrial Trade Show Calendar Highlights CIIF and Overlapping Sourcing Dates
- Jan Daley’s “A Time for Hope” Offers a Message of Compassion and Optimism
- McArthurGlen Designer Outlets Give Travel Advisors a Day Trip That Beats Expectations for Every Generation in Europe
- BKREA Wraps Up September With More Than $300 Million Closed Since July 1, Carrying Strong Momentum Into Q4
- Jacob Ohayon Announces Two Decades of Hands On Real Estate Investment Experience and Track Record
- John David Gregory Brings THE FACELESS MAN From Hollywood Protection to Feature Film Development With ISEG Global
- Cosmetic Eye Institute Highlights Specialized Blepharoplasty and Cosmetic Eye Surgery in Overland Park, KS
- Cosmetic Eye Institute Highlights Specialized Ptosis Repair Surgery for Patients in Overland Park and Leawood
- SIMZY Launches eSIM Data Plans for Turkey, Offering Flexible Connectivity for Travelers
- Fox Ridge, WI Acne Facial For Breakouts & Blemishes: Skin Care Announced
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS